These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 10708287

  • 1. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M.
    AIDS; 2000 Jan 28; 14(2):163-71. PubMed ID: 10708287
    [Abstract] [Full Text] [Related]

  • 2. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
    Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S, CNA3003 International Study Team.
    Antivir Ther; 2002 Mar 28; 7(1):43-51. PubMed ID: 12008787
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
    Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, Tisdale M, Irlbeck D, Underwood M, St Clair M, Ait-Khaled M.
    HIV Med; 2004 Nov 28; 5(6):394-9. PubMed ID: 15544690
    [Abstract] [Full Text] [Related]

  • 5. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F.
    Antivir Ther; 2006 Nov 28; 11(6):701-5. PubMed ID: 17310814
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
    Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder B.
    J Infect Dis; 2000 Mar 28; 181(3):912-20. PubMed ID: 10720512
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M, CNA2007 International Study Team.
    Antivir Ther; 2003 Apr 28; 8(2):111-20. PubMed ID: 12741623
    [Abstract] [Full Text] [Related]

  • 13. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.
    Antivir Ther; 2007 Apr 28; 12(1):25-30. PubMed ID: 17503744
    [Abstract] [Full Text] [Related]

  • 14. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ, Chappey C, Parkin NT, Miller MD.
    Antivir Ther; 2008 Apr 28; 13(2):189-97. PubMed ID: 18505170
    [Abstract] [Full Text] [Related]

  • 15. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.
    Curr Med Res Opin; 2004 Jul 28; 20(7):1103-14. PubMed ID: 15265255
    [Abstract] [Full Text] [Related]

  • 16. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, Staszewski S.
    Curr HIV Res; 2009 May 28; 7(3):320-6. PubMed ID: 19442129
    [Abstract] [Full Text] [Related]

  • 17. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
    Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG.
    Antivir Ther; 2002 Dec 28; 7(4):293-303. PubMed ID: 12553485
    [Abstract] [Full Text] [Related]

  • 18. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.
    Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW, Simpson D, Torres G, Catalan J, Marder K, Power C, Hall C, Romero C, Brew B.
    AIDS; 2001 Apr 13; 15(6):747-51. PubMed ID: 11371689
    [Abstract] [Full Text] [Related]

  • 19. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
    Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S, CNA3002 European Study Team.
    HIV Med; 2001 Jan 13; 2(1):27-34. PubMed ID: 11737373
    [Abstract] [Full Text] [Related]

  • 20. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group.
    Antivir Ther; 2003 Apr 13; 8(2):163-71. PubMed ID: 12741629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.